RCT (n=178)
double-blind
randomly assigned
Answers are grounded in this paper and cite their sources.
May support digoxin withdrawal in stable ACEI-treated HF; leaves open need for larger outcome trials.
Background. Although digoxin is effective in the treatment of patients with chronic heart failure who are receiving diuretic agents, it is not clear whether the drug has a role when patients are receiving angiotensin-converting-enzyme inhibitors, as is often the case in current practice. Methods. We studied 178 patients with New York Heart Association class II or III heart failure and left ventricular ejection fractions of 35 percent or less in normal sinus rhythm who were clinically stable while receiving digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor (captopril or enalapril). The patients were randomly assigned in a double-blind fashion either to continue receiving digoxin (85 patients) or to be switched to placebo (93 patients) for 12 weeks
No takes yet. Share an insight, caveat, or question.
O'Mara et al. (1993) conducted an RCT in chronic heart failure (n=178). Digoxin withdrawal (placebo) vs. Digoxin continuation was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: